Extended-release carbidopa-levodopa in Parkinson's disease

Affiliations

¹ CIC-9302/INSERM UMR825, Departments of Clinical Pharmacology and Neurosciences, University UPS of Toulouse III, Toulouse, France. olivier.rascol@univ-tlse3.fr

Comment

Olivier Rascol. Lancet Neurol. 2013 Apr.

. 2013 Apr;12(4):325-6.

doi: 10.1016/S1474-4422(13)70039-5. Epub 2013 Feb 26.

¹ CIC-9302/INSERM UMR825, Departments of Clinical Pharmacology and Neurosciences, University UPS of Toulouse III, Toulouse, France. olivier.rascol@univ-tlse3.fr

No abstract available

Comment on

Extended-release carbidopa-levodopa (IPX066) compared with immediate-release carbidopa-levodopa in patients with Parkinson's disease and motor fluctuations: a phase 3 randomised, double-blind trial.
Hauser RA, Hsu A, Kell S, Espay AJ, Sethi K, Stacy M, Ondo W, O'Connell M, Gupta S; IPX066 ADVANCE-PD investigators. Hauser RA, et al. Lancet Neurol. 2013 Apr;12(4):346-56. doi: 10.1016/S1474-4422(13)70025-5. Epub 2013 Feb 26. Lancet Neurol. 2013. PMID: 23485610 Clinical Trial.